The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Nature Communications

Volumn 6, Issue , 2015, Pages

  Medico, Enzo ^a,b   Russo, Mariangela ^a,b,c   Picco, Gabriele ^a,b   Cancelliere, Carlotta ^b   Valtorta, Emanuele ^d   Corti, Giorgio ^b   Buscarino, Michela ^b   Isella, Claudio ^a   Lamba, Simona ^a,b   Martinoglio, Barbara ^b   Veronese, Silvio ^d   Siena, Salvatore ^d   Sartore Bianchi, Andrea ^d   Beccuti, Marco ^e   Mottolese, Marcella ^f   Linnebacher, Michael ^g   Cordero, Francesca ^e   Di Nicolantonio, Federica ^a,b   Bardelli, Alberto ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALK PROTEIN; B RAF KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CETUXIMAB; DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; NTRK1 PROTEIN; PANITUMUMAB; PHOSPHOTRANSFERASE; PROTEIN; RAS PROTEIN; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FGFR2 PROTEIN, HUMAN; PROTEIN RET; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN;

CANCER; DRUG; GENE EXPRESSION; GENOMICS; MOLECULAR ANALYSIS; PUBLIC HEALTH; TUMOR;

ARTICLE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULARLY TARGETED THERAPY; WILD TYPE; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYMOLOGY; GENETIC HETEROGENEITY; GENETICS; METABOLISM; PROTO ONCOGENE; TUMOR CELL LINE;

CELL LINE, TUMOR; CETUXIMAB; COLORECTAL NEOPLASMS; GENES, ERBB-1; GENETIC HETEROGENEITY; HUMANS; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2;

EID: 84928811801     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8002     Document Type: Article

References (46)

1. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
2. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
3. Park, E. S. et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol. Cancer Ther. 9, 257-267 (2010).
4. Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151-1161 (2013).
5. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
6. Smith, C. G. et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy±cetuximab. Clin. Cancer Res. 19, 4104-4113 (2013).
7. Roth, A. D. et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J. Natl Cancer Inst. 104, 1635-1646 (2012).
8. Budinska, E. et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63-76 (2013).
9. De Sousa, E. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614-618 (2013).
10. Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).
11. Roepman, P. et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134, 552-562 (2014).
12. Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619-625 (2013).
13. Liu, X., Yu, X., Zack, D. J., Zhu, H. & Qian, J. TiGER: a database for tissuespecific gene expression and regulation. BMC Bioinformatics 9, 271 (2008).
14. Vécsey-Semjén, B. et al. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene 21, 4646-4662 (2002).
15. Wilding, J. L. & Bodmer, W. F. Cancer cell lines for drug discovery and development. Cancer Res. 74, 2377-2384 (2014).
16. Mouradov, D. et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 74, 3238-3247 (2014).
17. Barault, L. et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a populationbased series of colon cancers. Int. J. Cancer 122, 2255-2259 (2008).
18. De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
19. Sartore-Bianchi, A. et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 4, e7287 (2009).
20. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
21. De Roock, W., De Vriendt, V., Normanno, N., Ciardiello, F. & Tejpar, S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12, 594-603 (2011).
22. Tabernero, J. et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann. Oncol. 21, 1537-1545 (2010).
23. Hoshida, Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS ONE 5, e15543 (2010).
24. Kothari, V. et al. Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov. 3, 280-293 (2013).
25. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
26. Lin, E. et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol. Cancer Res. 7, 1466-1476 (2009).
27. Ardini, E. et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol. Oncol. 8, 1495-1507 (2014).
28. Mathur, A. et al. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. PLoS ONE 9, e98515 (2014).
29. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, 11 (2013).
30. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
31. Beaufort, C. M. et al. Ovarian Cancer Cell Line Panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS ONE 9, e103988 (2014).
32. Ashraf, S. Q. et al. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc. Natl Acad. Sci. USA 109, 21046-21051 (2012).
33. Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
34. Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013).
35. Fu, L. & Medico, E. FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data. BMC Bioinformatics 8, 3 (2007).
36. Whitehouse, P. A. et al. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs 14, 369-375 (2003).
37. Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500-501 (2006).
38. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
39. Tibshirani, R., Hastie, T., Narasimhan, B. & Chu, G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl Acad. Sci. USA 99, 6567-6572 (2002).
40. Roig, A. I. et al. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology 138, 1012-1021 (2010).
41. Brough, R. et al. Functional viability profiles of breast cancer. Cancer Discov. 1, 260-273 (2011).
42. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).
43. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
44. Ge, H. et al. FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics 27, 1922-1928 (2011).
45. De Falco, V. et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J. Clin. Endocrinol. Metab. 98, E811-E819 (2013).
46. Valtorta, E. et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int. J. Cancer. 133, 1259-1265 (2013).